Abstract
Treatment approaches with recombinant IFN-α2b and natural IFN-β in a patient with chronic hepatitis C (genotype 1b) and cirrhosis had, in both cases, to be terminated prematurely due to breakthrough phenomena and thrombo-leucocytopenia up to WHO grade 3. After the patient was switched to highly purified natural IFN-α (Multiferon®) the thrombocyte and leukocyte counts increased significantly, and sustained complete biochemical and virological response could be achieved.